Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03797443
Recruitment Status : Withdrawn (Regulatory Review needed)
First Posted : January 9, 2019
Last Update Posted : May 31, 2019
Sponsor:
Collaborators:
Cancer Research UK
Stand Up To Cancer
Lustgarten Foundation
Destroy Pancreatic Cancer
Translational Genomics Research Institute
Information provided by (Responsible Party):
Piedmont Cancer Institute

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : December 2022